

# Anti-IL-22 Reference Antibody (fezakinumab)

Recombinant Antibody  
Catalog # APR10162

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">Q9GZX6</a>
<b>Reactivity</b>	Human, Rat
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	20011

## Additional Information


---

<b>Target/Specificity</b>	IL-22
<b>Endotoxin</b>	
<b>Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


## Protein Information

---


<b>Name</b>	IL22
<b>Synonyms</b>	ILTIF, ZCYTO18
<b>Function</b>	Cytokine that plays a critical role in modulating tissue responses during inflammation (PubMed: <a href="#">17204547</a> ). Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage (PubMed: <a href="#">17204547</a> ). Unlike most of the cytokines, has no effect on immune cells. Signals through a heterodimeric receptor composed of two subunits, the specific receptor IL22RA1 which is present on non-immune cells in many organs and the shared subunit IL10RB (PubMed: <a href="#">10875937</a> , PubMed: <a href="#">18599299</a> ). Ligation of IL22RA1 with IL22 induces activation of the tyrosine kinases JAK1 and TYK2, which in turn activates STAT3. In turn, promotes cell survival and proliferation through STAT3, ERK1/2 and PI3K/AKT pathways (PubMed: <a href="#">25793261</a> , PubMed: <a href="#">31311100</a> ). Promotes phosphorylation of GSK3B at 'Ser-9' and CTTN (By similarity). Promotes epithelial cell spreading (By similarity).
<b>Cellular Location</b>	Secreted.



Anti-IL-22 Reference Antibody (fezakinumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-22 Reference Antibody (fezakinumab) is more than 99.05% ,determined by SEC-HPLC.



Immobilized human IL 22, Fc Tag at 2 µg/mL can bind Anti-IL-22 Reference Antibody (fezakinumab),EC50=0.103 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.